Learning from the Komodo Dragon: Evolutionary Principles for Designing Environmentally Sustainable Anti-Infective Therapeutics

Antimicrobial resistance (AMR) is rapidly undermining the effectiveness of existing antibiotics, while the discovery of truly novel antimicrobial agents remains limited. Addressing this crisis requires moving beyond the search for individual molecules toward understanding how evolution has naturally optimized infection control. Among living vertebrates, the Komodo dragon (Varanus komodoensis) is often described, largely in secondary sources, as unusually resistant to infection, but this has not been demonstrated: the animal is repeatedly exposed to contaminated wounds, carrion and pathogen-rich environments, yet health assessments of free-ranging and captive animals have reported no major underlying medical problems, and its salivary flora contains no uniquely virulent species. We emphasise at the outset that no infection-incidence or infection-attributable mortality data exist for this species; we therefore treat apparent resilience as an explicit, falsifiable working premise and specify the surveillance studies that would confirm or refute it. The framework does not depend on this premise being true: each principle is justified by independent evidence, and the premise serves only as the motivation for choosing the exemplar and as a hypothesis that the proposed studies can refute; if it is refuted, the principles remain testable in other taxa and in vitro, and the dragon becomes illustrative rather than essential. In this Perspective, we introduce the Komodo Principle, a conceptual framework that organises seven interconnected evolutionary characteristics, early pathogen sensing, layered defense, precision antimicrobial activity, coordinated tissue repair, timely immune resolution, microbial coexistence, and environmental biodegradability. Because only part of the supporting evidence is Komodo-specific, we state the evidentiary provenance of each principle explicitly and position the dragon as a vivid entry point to cross-taxon design principles rather than as a uniquely gifted species. We also classify the principles as resistance-type (pathogen-limiting) or tolerance-type (damage-limiting) strategies, which differ in their predicted relationship between pathogen load and host damage and in their expected selection on pathogens, and we treat the thermal mismatch between an ectothermic donor and a mammalian recipient as a translational constraint rather than as an evolutionary confound. Rather than viewing the Komodo dragon simply as a source of antimicrobial peptides, we propose that its greatest translational value may lie in the biological design principles that its defence biology exemplifies, whatever the true level of its resistance to infection. We use “resilience” here in its ordinary, pre-theoretical sense (apparent freedom from severe infection), not as a technical immunological term, and we do not use it interchangeably with “immunity,” “immune competence” or “resistance” elsewhere in the text, each of which implies a specific, and in most cases untested, mechanism. We synthesize current evidence on Komodo immunobiology, critically evaluate its strengths and limitations, and discuss how systems biology, multi-omics, artificial intelligence, and advanced drug delivery technologies could translate these evolutionary principles into environmentally sustainable anti-infective therapeutics. To make the framework testable rather than merely programmatic, we conclude with six concrete, falsifiable near-term experiments, only one of which requires new biological material from this endangered species, that would establish whether the Komodo Principle adds value beyond generalist antimicrobial-peptide and stewardship research. This framework provides a new roadmap for developing next-generation therapies that simultaneously enhance antimicrobial efficacy, support host recovery, preserve microbial ecology, and advance One Health-oriented innovation.